Losartan and paclitaxel for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether adding losartan, a blood pressure medication, to the chemotherapy drug paclitaxel can help treat ovarian cancer that has returned after platinum-based treatment. The goal is to see if this combination can slow or stop the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned within 6 months of completing platinum-based chemotherapy.
- You have at least one tumor that can be measured on a scan or exam.
- You have received no more than 4 prior lines of treatment for platinum-resistant disease.
- You are generally well enough to carry out daily activities (ECOG performance status 0-2).
- Your blood counts, kidney, and liver function are within required limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding telmisartan (a blood pressure medicine) to standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based drugs. The goal is to see if the combination can help control the cancer better.
This trial tests a new drug called DT2216 combined with the chemotherapy drug paclitaxel for ovarian cancer that has stopped responding to platinum-based chemo. The goal is to see if this combination can shrink or slow the cancer, and to find a safe dose.
This study tests a new liquid form of paclitaxel (a common chemotherapy drug) in women whose ovarian, fallopian tube, or primary peritoneal cancer has stopped responding to platinum-based chemotherapy. The goal is to see if this new formulation is safe and effective for this difficult-to-treat situation.
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
Hear when a new Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.